Drugs / MIBAMPATOR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00843518 | Feb 2009 → Jun 2011 | Alzheimer disease | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT00051909 | Nov 2002 → Jun 2003 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIBAMPATOR | ChEMBL registry synonym — accepted as the source's own label CHEMBL1277001 ↗ |
| Known as | LY451395 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00843518 ↗ |
| Modality | Small molecule | — CHEMBL1277001 ↗ |
| Route | Oral | “3 mg LY451395 orally twice daily for 12 weeks” NCT00843518 ↗ |